KRYSTAL BIOTECH INC (KRYS) Stock Price, Quote, News and Overview
NASDAQ:KRYS - Nasdaq - US5011471027 - Common Stock - Currency: USD
KRYS Quote, Performance and Key Statistics
125.05
-0.24 (-0.19%)
The current stock price of KRYS is 125.05 USD. In the past month the price decreased by -25.59%. In the past year, price decreased by -23.2%.
KRYS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 17.84 | 323.71B | ||
| AMGN | AMGEN INC | 13.09 | 146.07B | ||
| GILD | GILEAD SCIENCES INC | 13.87 | 133.68B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 111.96B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.28 | 63.52B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 37.81B | ||
| ARGX | ARGENX SE - ADR | 100.1 | 35.88B | ||
| ONC | BEIGENE LTD-ADR | 6 | 26.10B | ||
| BNTX | BIONTECH SE-ADR | N/A | 23.72B | ||
| NTRA | NATERA INC | N/A | 20.94B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 19.20B | ||
| BIIB | BIOGEN INC | 7.95 | 18.43B |
Related stock screener links
About KRYS
Company Profile
Krystal Biotech, Inc. operates as a biotechnology company, which engages in developing and commercializing pharmaceutical products. The company is headquartered in Pittsburgh, Pennsylvania and currently employs 275 full-time employees. The company went IPO on 2017-09-20. The company is focused on the discovery, development, and commercialization of genetic medicines to treat diseases with high unmet medical needs. Its product candidates in various stages of clinical and preclinical development include VYJUVEK, KB407, KB408, KB707, KB105, KB104, KB104, and KB301. Its commercial product VYJUVEK is a non-invasive, topical, redo sable gene therapy designed to deliver two copies of theCOL7A1 gene when applied directly to DEB wounds. VYJUVEK is designed to treat DEB at the molecular level by providing the patient’s skin cells the template to make normal COL7 protein, thereby addressing the fundamental disease-causing mechanism. KB407 is developed for the treatment of Cystic Fibrosis. KB408 is developed for the treatment of Alpha-1 Antitrypsin Deficiency. KB707 is developed for the treatment of solid tumors. KB105 is developed for TGM1-Deficient Autosomal Recessive Congenital Ichthyosis.
Company Info
KRYSTAL BIOTECH INC
2100 Wharton St Ste 701
Pittsburgh PENNSYLVANIA 15203 US
CEO: Krish S. Krishnan
Employees: 275
Phone: 14125865830
KRYSTAL BIOTECH INC / KRYS FAQ
What is the stock price of KRYSTAL BIOTECH INC today?
The current stock price of KRYS is 125.05 USD. The price decreased by -0.19% in the last trading session.
What is the ticker symbol for KRYSTAL BIOTECH INC stock?
The exchange symbol of KRYSTAL BIOTECH INC is KRYS and it is listed on the Nasdaq exchange.
On which exchange is KRYS stock listed?
KRYS stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for KRYSTAL BIOTECH INC stock?
17 analysts have analysed KRYS and the average price target is 221.54 USD. This implies a price increase of 77.16% is expected in the next year compared to the current price of 125.05. Check the KRYSTAL BIOTECH INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is KRYSTAL BIOTECH INC worth?
KRYSTAL BIOTECH INC (KRYS) has a market capitalization of 3.61B USD. This makes KRYS a Mid Cap stock.
How many employees does KRYSTAL BIOTECH INC have?
KRYSTAL BIOTECH INC (KRYS) currently has 275 employees.
What are the support and resistance levels for KRYSTAL BIOTECH INC (KRYS) stock?
KRYSTAL BIOTECH INC (KRYS) has a resistance level at 130.71. Check the full technical report for a detailed analysis of KRYS support and resistance levels.
Is KRYSTAL BIOTECH INC (KRYS) expected to grow?
The Revenue of KRYSTAL BIOTECH INC (KRYS) is expected to grow by 46.09% in the next year. Check the estimates tab for more information on the KRYS EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy KRYSTAL BIOTECH INC (KRYS) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of KRYS, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of KRYS, evaluating the profitability, health, valuation and growth aspects
- KRYSTAL BIOTECH INC (KRYS) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- KRYSTAL BIOTECH INC (KRYS) Sales and EPS estimates to see what analysts future expectations are.
- KRYSTAL BIOTECH INC (KRYS) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- KRYSTAL BIOTECH INC (KRYS) Insider and Institutional Ownership to learn about the owners and their transactions.
- KRYSTAL BIOTECH INC (KRYS) Stock Chart to make your own analysis
- KRYSTAL BIOTECH INC (KRYS) Latest news and press-releases to stay up to date.
Does KRYSTAL BIOTECH INC (KRYS) stock pay dividends?
KRYS does not pay a dividend.
When does KRYSTAL BIOTECH INC (KRYS) report earnings?
KRYSTAL BIOTECH INC (KRYS) will report earnings on 2025-08-04, before the market open.
What is the Price/Earnings (PE) ratio of KRYSTAL BIOTECH INC (KRYS)?
The PE ratio for KRYSTAL BIOTECH INC (KRYS) is 30.06. This is based on the reported non-GAAP earnings per share of 4.16 and the current share price of 125.05 USD. Check the full fundamental report for a full analysis of the valuation metrics for KRYS.
What is the Short Interest ratio of KRYSTAL BIOTECH INC (KRYS) stock?
The outstanding short interest for KRYSTAL BIOTECH INC (KRYS) is 9.64% of its float. Check the ownership tab for more information on the KRYS short interest.
KRYS Technical Analysis
KRYS Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to KRYS. KRYS is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average.
KRYS Financial Highlights
Over the last trailing twelve months KRYS reported a non-GAAP Earnings per Share(EPS) of 4.16. The EPS increased by 358.39% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 37.18% | ||
| ROA | 11.54% | ||
| ROE | 12.59% | ||
| Debt/Equity | 0 |
KRYS Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 85% to KRYS. The Buy consensus is the average rating of analysts ratings from 17 analysts.
For the next year, analysts expect an EPS growth of 104.99% and a revenue growth 46.09% for KRYS